PRT120 / Prota Therap - LARVOL DELTA

PPOIT-003LT: Follow-on study of a multicentre randomised, controlled trial (PPOIT-003) evaluating the long-term safety and efficacy of Probiotic and Peanut Oral Immunotherapy (PPOIT) compared with Oral Immunotherapy (OIT) alone and with placebo in peanut allergic individuals (ANZCTR) - P=N/A | N=171 | Completed | Sponsor: Murdoch Children's Research Institute | Active, not recruiting ➔ Completed

Trial completion • Allergy • Food Hypersensitivity • Immunology

Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients (PRNewswire) - "Prota Therapeutics....Published in The Lancet Child & Adolescent Health...the Phase 2b clinical trial results validate Prota's lead product candidate PRT120...The placebo-controlled trial confirms the effectiveness of PRT120 comprising Prota's rapid escalation dosing regimen in inducing clinical remission of peanut allergy in children and improving quality of life for patients....Prota Therapeutics is looking to raise funds to support the further clinical development and commercialization of PRT120."

P2b data • Food Hypersensitivity